Healthy
Conditions
Brief summary
The objective of the study is to investigate the drug interaction between LC15-0444 and pioglitazone by comparing the safety, tolerability and pharmacokinetics of LC15-0444 and pioglitazone are administered concomitantly and each alone in healthy male subjects.
Detailed description
This study is a randomized, open-label, three-treatment, three-period, three-sequence and crossover design in healthy volunteers to evaluate tolerability, safety and pharmacokinetics after the multiple administration of LC15-0444 and pioglitazone concomitantly or each alone. Eligibility for participation of this study will be determined by demographic information, medical history, physical examination, electrocardiogram (ECG) and clinical laboratory tests within 3 weeks(-21 d \ -2 d) before drug administration(1 d). Eligible subjects will be randomized to one of three sequence groups. According to the characteristics of anti-diabetic drugs, it is expected to be administered with other anti-diabetic drugs. Therefore, Drug-Drug Interaction with Pioglitazone should be identified in this trial.
Interventions
DRUGLC15-0444, Pioglitazone
LC15-0444 200 mg (100 mg x 2) qd (12 days once daily) Pioglitazone 30 mg (15 mg x 2) qd (12 days once daily) LC15-0444 200 mg (100 mg x 2) qd + pioglitazone 30 mg (15 mg x 2) qd (12 days once daily)
Sponsors
LG Life Sciences
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
20 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy male subjects between the ages of 20 and 45 years at screening 2. Subjects with Body Mass Index (BMI) between 18.0(inclusive) and 27.0 kg/m2 (exclusive); and a total body weight between 55 kg (inclusive) and 90 kg (exclusive). BMI(kg/m2) = body weight(kg)/{height(m)}2. 3. Subjects with fasting plasma glucose (FPG) level of 70-125 mg/dL (both inclusive) at the time of screening. 4. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial.
Exclusion criteria
1. Subjects with evidence or history of clinically significant hepatic (including carrier of viral hepatitis), renal, neurologic (mood disorder, obsessive-compulsive disorder etc.), immunologic, pulmonary, endocrine, hematological, neoplastic, cardiovascular or psychiatric disease. 2. Subjects with evidence or history of gastrointestinal disease (Crohn's disease, ulcer, acute or chronic pancreatitis etc.) or surgery (except appendectomy and herniotomy) possibly affecting drug absorption. 3. Subjects with history of hypersensitivities including drug allergies (caused by aspirin, antibiotics, etc.), or history of clinically significant hypersensitivities. 4. Subjects who meet the following criteria at the time of the screening examination; Serum AST(SGOT) or ALT(SGPT): \> 1.5 times upper normal limit Creatinine clearance calculated by Cockcroft-Gault equation * \< 80 mL/min Clinical significant abnormalities on ECG including 12-lead ECG demonstrating QTc \>450 msec at screening or any rhythms except for sinus rhythm 5. Subjects who show the following vital sign results at sitting position after resting for 3 min; SBP: ≤ 100 mmHg or ≥ 150 mmHg DBP: ≤ 60 mmHg or ≥ 95 mmHg 6. Subjects with history of drug abuse or a positive urine result in drug screen for drug abuse or cotinine. 7. Subjects who have taken any prescribed medicines or herbal medicines within 2 weeks before the first administration of the investigational product, any non-prescribed medicines or vitamin supplements within 1 week before the first administration of the investigational product. (If other conditions are satisfied, subjects may be eligible for the trial by the investigator's judgment.) 8. Subjects who have participated in any other clinical trial within 2 months before the first administration of the investigational product. 9. Subjects who have donated a unit of blood within 2 months or blood components within 1 month before the first administration of the investigational product. 10. Subjects who consume more than 21 units of alcohol per week (1 unit = 10 g of pure alcohol) or unable to abstain from drinking throughout the trial. 11. Smokers (except for those who quit smoking for at least 3 months the first administration of the investigational product) 12. Subjects who take caffeine-containing or grapefruit-containing products within 3 days before the first administration of the investigational product.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AUCτ,ss, Cmax,ss of LC15-0444 and pioglitazone | During all dosing visits |
Secondary
| Measure | Time frame |
|---|---|
| Tmax,ss, t1/2, CL/F, Aeτ,ss, CLR, Ctrough,ss of LC15-0444 and pioglitazone AUCτ,ss, Cmax,ss, metabolic ratio of LC15-0444, Pioglitazone metabolites AUC,ss, Cmax,ss, metabolic ratio of pioglitazone metabolites | During all dosing visits |
Countries
South Korea
Outcome results
None listed